Corium International Inc (NASDAQ:CORI) major shareholder Life Sciences Maste Perceptive purchased 510,000 shares of the stock in a transaction dated Thursday, January 18th. The stock was bought at an average cost of $12.54 per share, with a total value of $6,395,400.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Corium International Inc (NASDAQ:CORI) traded up $0.78 during midday trading on Friday, reaching $13.09. The company had a trading volume of 662,100 shares, compared to its average volume of 229,458. Corium International Inc has a twelve month low of $2.67 and a twelve month high of $13.24. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 2.41. The company has a market cap of $481.45, a PE ratio of -7.84 and a beta of 1.26.
Corium International (NASDAQ:CORI) last posted its earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. Corium International had a negative return on equity of 482.64% and a negative net margin of 149.99%. analysts anticipate that Corium International Inc will post -1.47 EPS for the current fiscal year.
A number of analysts have recently commented on the company. Zacks Investment Research cut Corium International from a “hold” rating to a “sell” rating in a research note on Friday, December 29th. ValuEngine raised Corium International from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Needham & Company LLC increased their target price on Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, November 20th. Jefferies Group set a $10.00 target price on Corium International and gave the stock a “buy” rating in a research note on Sunday, October 29th. Finally, HC Wainwright set a $14.00 target price on Corium International and gave the stock a “buy” rating in a research note on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. Corium International presently has an average rating of “Buy” and an average target price of $12.86.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Stonepine Capital Management LLC bought a new position in shares of Corium International during the 2nd quarter worth approximately $3,085,000. State Street Corp bought a new position in shares of Corium International during the 2nd quarter worth approximately $1,840,000. EAM Investors LLC bought a new position in shares of Corium International during the 2nd quarter worth approximately $563,000. TIAA CREF Investment Management LLC bought a new position in shares of Corium International during the 2nd quarter worth approximately $411,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Corium International by 161.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 66,160 shares of the biopharmaceutical company’s stock worth $494,000 after acquiring an additional 40,891 shares in the last quarter. 89.08% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Corium International Inc (CORI) Major Shareholder Life Sciences Maste Perceptive Purchases 510,000 Shares” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/19/corium-international-inc-cori-major-shareholder-life-sciences-maste-perceptive-purchases-510000-shares.html.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.